grant
Project 2: Novel hyperpolarized C-13 imaging as metabolic markers of response in IDH mutant glioma
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 20 Sept 2002Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY20252-ketoglutarate2-oxoglutarate21+ years oldAbscissionAdultAdult GliomaAdult HumanAfter CareAfter-TreatmentAftercareBiologicalBiological MarkersBiologyBiostatistics CoreBody TissuesBrainBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsCharacteristicsClassificationClinicalClinical ResearchClinical StudyClinical TrialsCollaborationsCommon Rat StrainsDNA mutationDevelopmentDiagnosisDiagnosticDropsyDrugsEarly treatmentEdemaEncephalonEvaluationExcisionExtirpationGeneralized GrowthGenetic ChangeGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetic defectGenetic mutationGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGliosisGlutamatesGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrantGrowthHydropsImageInfrastructureIntermediary MetabolismInternationalInvestigatorsIsocitrate DehydrogenaseL-GlutamateLeadershipLesionLocationMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMalignantMalignant - descriptorMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMetabolicMetabolic MarkerMetabolic ProcessesMetabolismModelingMonitorMultimodal ImagingMutationNMR ImagingNMR TomographyNeuroglial NeoplasmNeuroglial TumorNewly DiagnosedNormal TissueNormal tissue morphologyNuclear Magnetic Resonance ImagingOperative ProceduresOperative Surgical ProceduresPathologicPathologyPatient SchedulesPatientsPharmaceutical PreparationsPharmacodynamicsPhasePopulationPositionPositioning AttributeProductionPrognosisPropertyPyruvateRatRats MammalsRattusRecombinant DNA TechnologyRecurrenceRecurrentRemovalReportingResearch PersonnelResearch ResourcesResearchersResourcesScanningSpecificitySurgicalSurgical InterventionsSurgical ManagementSurgical ProcedureSurgical RemovalSystematicsTechnologyTestingTimeTissue GrowthTissue SampleTissuesTranslatingTranslationsTumor BurdenTumor LoadZeugmatographyactivity markeradulthoodalpha ketoglutarateanatomic imaginganatomical imagingbio-markersbiologicbiologic markerbiomarkercancer cell metabolismcancer metabolismclinical implementationcohortdesigndesigningdevelopmentaldrug developmentdrug/agentearly biomarkersearly detection biomarkersearly detection markersearly therapyexperiencegenetically engineeredgenome mutationglial-derived tumorglioblastoma multiformeglutamatergichigh riskimage guidanceimage guidedimagingimaging approachimaging based approachimaging biomarkerimaging capabilitiesimaging markerimaging probeimaging-based biological markerimaging-based biomarkerimaging-based markerimprovedindustrial partnershipindustry partnerindustry partnershipinnovateinnovationinnovativemetabolic imagingmulti-modal imagingmulti-modality imagingmultimodality imagingmutantneuroglia neoplasmneuroglia tumornew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnon-invasive imagingnoninvasive imagingnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachontogenypharmacodynamic biomarkerpharmacodynamic markerpost treatmentpre-clinicalpreclinicalrecruitresectionresponseresponse biomarkerresponse markersresponse to therapyresponse to treatmentspongioblastoma multiformesurgerytherapeutic agent developmenttherapeutic developmenttherapeutic responsetherapy responsetranslationtreatment responsetreatment responsivenesstumortumor cell metabolismtumor metabolismtumors in the brainvolunteerα-ketoglutarateα-oxoglutarateαKG
Description preview
Project Summary/Abstract
Isocitrate dehydrogenase (IDH) mutant glioma are mostly non-enhancing, which makes it difficult to distinguish
the boundaries of infiltrative lesions from normal tissue and edema in both newly diagnosed and post-treatment
settings. The standard efficacy endpoints of response rate or overall survival are also challenging…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click